Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Nov;21(11):2696-707.
doi: 10.1097/MIB.0000000000000543.

Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Maneesh Dave  1 , Kathan Mehta, Jay Luther, Anushka Baruah, Allan B Dietz, William A Faubion Jr
Affiliations
Meta-Analysis

Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Maneesh Dave et al. Inflamm Bowel Dis. 2015 Nov.

Abstract

Recent advances in inflammatory bowel disease (IBD) therapeutics include novel medical, surgical, and endoscopic treatments. Among these, stem cell therapy is still in its infancy, although multiple studies suggest that the immunomodulatory effect of stem cell therapy may reduce inflammation and tissue injury in patients with IBD. This review discusses the novel avenue of stem cell therapy and its potential role in the management of ulcerative colitis and Crohn's disease. We conducted a comprehensive literature search to identify studies examining the role of stem cell therapy (without conditioning and immunomodulatory regimens) in IBD. Taken together, these studies suggest a promising role for stem cell therapy in IBD although the substantial challenges, such as cost and inadequate/incomplete characterization of effect, limit their current use in clinical practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Different mechanisms of immunoregulation by mesenchymal stem cells
Figure 2
Figure 2
A: Overall quality of the included studies assessed by Cochrane risk of bias assessment tool. B: Risk of bias within studies assessed by Cochrane risk of bias assessment tool. Plus sign denotes low risk. Minus sign denotes high risk. Blank denotes unclear risk.
Figure 2
Figure 2
A: Overall quality of the included studies assessed by Cochrane risk of bias assessment tool. B: Risk of bias within studies assessed by Cochrane risk of bias assessment tool. Plus sign denotes low risk. Minus sign denotes high risk. Blank denotes unclear risk.
Figure 3
Figure 3
Forrest plot of studies evaluating healing of peri-anal fistulas (peri-anal CD) after local administration/injection of MSCs.
Figure 4
Figure 4
Forrest plot of studies evaluating induction of clinical remission after systemic administration of MSCs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dave M, Papadakis KA, Faubion WA., Jr Immunology of Inflammatory Bowel Disease and Molecular Targets for Biologics. Gastroenterol Clin North Am. 2014;43:405–424. - PMC - PubMed
    1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721. - PubMed
    1. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710. - PubMed
    1. Poggioli G, Pierangeli F, Laureti S, et al. Review article: indication and type of surgery in Crohn’s disease. Aliment Pharmacol Ther. 2002;16(Suppl 4):59–64. - PubMed
    1. Nicholls RJ. Review article: ulcerative colitis--surgical indications and treatment. Aliment Pharmacol Ther. 2002;16(Suppl 4):25–28. - PubMed

Publication types